MyFinsight
Home
Blog
About
Contact
Proceeds from maturities
of short-term...
$24,898K
Net cash provided by
investing activities
$4,963K
Canceled cashflow
$19,935K
Net decrease in
cash, cash...
-$17,063K
Canceled cashflow
$4,963K
Change in payable to
licensor
$7,000K
Stock-based compensation
expense
$2,957K
Depreciation and
amortization
$690K
Deferred revenue
$425K
Non-cash interest
$274K
Amortization of right-of-use
lease assets
$179K
Other receivables
-$59K
Accretion and interest on
short-term investments
-$13K
Purchases of short-term
investments
$19,000K
Capital expenditures
$935K
Net cash used in
operating activities
-$19,804K
Canceled cashflow
$11,597K
Net cash (used in)
provided by financing...
-$2,222K
Net loss
-$17,075K
Accounts payable and
accrued expenses
-$7,315K
Change in fair value of
warrant liabilities
-$5,386K
Prepaid expenses and
other current assets
$657K
Inventory
$561K
Lease liabilities
-$182K
Accrued taxes and other
current liabilities
-$126K
Accounts receivable
$53K
Other assets
$46K
Payments of long-term
debt
$2,222K
Back
Back
Cash Flow
ABEONA THERAPEUTICS INC. (ABEO)
ABEONA THERAPEUTICS INC. (ABEO)
source: myfinsight.com